TP53 and non-small cell lung adenocarcinoma: Studies have confirmed that when patients with non-small cell lung adenocarcinoma have TP53 gene mutations, also accompanied by an increased PD-L1 expression, which often indicates those patients are more likely sensitive to PD-1/PD-L1 therapy (Dong et al., 2017).